R37CA258761
Project Grant
Overview
Grant Description
Ms. Lilac: Muscle Mass in the Life and Longevity After Cancer (LILAC) Study - Abstract
There is emerging evidence that cancer and its treatments may accelerate the normal aging process, increasing the magnitude and rate of decline in functional capacity. This accelerated aging process is hypothesized to hasten the occurrence of common adverse age-related outcomes in cancer survivors, including loss of muscle mass and decrease in physical function. However, there is no data describing age-related loss of muscle mass and its relation to physical function in the long-term in cancer survivors.
This project will directly address three key methodological challenges in research on cancer survivorship: 1) obtaining accurate measures of skeletal muscle mass in large population-based cohorts of community dwelling older adults, 2) disentangling the effect of age versus cancer on the relationship between muscle mass, physical function (gait speed, balance, strength), and functional decline, and 3) the large sample size required to understand predictors of low muscle mass using big data (machine learning) approaches.
The D3-creatine dilution method (D3CR) will be used to obtain a direct measure of muscle mass remotely, using a protocol that has been previously validated in clinical and epidemiologic research. This study will measure D3CR muscle mass in 6614 participants (3044 cancer survivors and 3570 cancer-free controls) in the Women's Health Initiative (WHI), a large prospective cohort study (N=161,808) of postmenopausal women with over 25 years of follow-up. Participants will be drawn from two sub-cohorts embedded within the WHI using an incidence density sampling approach. Cancer survivors will be drawn from an existing NCI-funded survivorship cohort, the Life and Longevity After Cancer (LILAC) cohort, and cancer-free controls will be drawn from the WHI Long Life Study 2.
The overall objective of this application is to examine the antecedents and consequences of low muscle mass in cancer survivors, using innovative methods to overcome major sources of bias common in cancer research. The study aims are to: 1) create age-standardized muscle mass percentile curves and z-scores to characterize the distribution of D3CR muscle mass in cancer survivors and non-cancer controls, 2) compare muscle mass, physical function, and functional decline in cancer survivors and non-cancer controls, and 3) use machine learning approaches to generate multivariate risk-prediction algorithms to detect low muscle mass.
This project addresses an urgent need identified by the NCI for research in older and long-term cancer survivors. The results of this study will be used to develop interventions to mitigate the harmful effects of low muscle mass in older adults and promote healthy survivorship in cancer survivors in the old (>65) and oldest-old (>85) age groups.
There is emerging evidence that cancer and its treatments may accelerate the normal aging process, increasing the magnitude and rate of decline in functional capacity. This accelerated aging process is hypothesized to hasten the occurrence of common adverse age-related outcomes in cancer survivors, including loss of muscle mass and decrease in physical function. However, there is no data describing age-related loss of muscle mass and its relation to physical function in the long-term in cancer survivors.
This project will directly address three key methodological challenges in research on cancer survivorship: 1) obtaining accurate measures of skeletal muscle mass in large population-based cohorts of community dwelling older adults, 2) disentangling the effect of age versus cancer on the relationship between muscle mass, physical function (gait speed, balance, strength), and functional decline, and 3) the large sample size required to understand predictors of low muscle mass using big data (machine learning) approaches.
The D3-creatine dilution method (D3CR) will be used to obtain a direct measure of muscle mass remotely, using a protocol that has been previously validated in clinical and epidemiologic research. This study will measure D3CR muscle mass in 6614 participants (3044 cancer survivors and 3570 cancer-free controls) in the Women's Health Initiative (WHI), a large prospective cohort study (N=161,808) of postmenopausal women with over 25 years of follow-up. Participants will be drawn from two sub-cohorts embedded within the WHI using an incidence density sampling approach. Cancer survivors will be drawn from an existing NCI-funded survivorship cohort, the Life and Longevity After Cancer (LILAC) cohort, and cancer-free controls will be drawn from the WHI Long Life Study 2.
The overall objective of this application is to examine the antecedents and consequences of low muscle mass in cancer survivors, using innovative methods to overcome major sources of bias common in cancer research. The study aims are to: 1) create age-standardized muscle mass percentile curves and z-scores to characterize the distribution of D3CR muscle mass in cancer survivors and non-cancer controls, 2) compare muscle mass, physical function, and functional decline in cancer survivors and non-cancer controls, and 3) use machine learning approaches to generate multivariate risk-prediction algorithms to detect low muscle mass.
This project addresses an urgent need identified by the NCI for research in older and long-term cancer survivors. The results of this study will be used to develop interventions to mitigate the harmful effects of low muscle mass in older adults and promote healthy survivorship in cancer survivors in the old (>65) and oldest-old (>85) age groups.
Funding Goals
TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS; (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION; (3) EPIDEMIOLOGY; (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS; (5) IMMUNOLOGY AND VACCINES; (6) FIELD STUDIES AND STATISTICS; (7) CANCER CHEMOPREVENTION AND INTERCEPTION; (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT; (9) ORGAN SITE STUDIES AND CLINICAL TRIALS; (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES; AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM; TO STIMULATE TECHNICAL INNOVATION; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING; TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Buffalo,
New York
142148001
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 353% from $728,154 to $3,299,836.
The Research Foundation For The State University Of New York was awarded
Longevity After Cancer Study: Impact of Muscle Mass on Aging Survivors
Project Grant R37CA258761
worth $3,299,836
from National Cancer Institute in March 2022 with work to be completed primarily in Buffalo New York United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.393 Cancer Cause and Prevention Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 5/5/26
Period of Performance
3/9/22
Start Date
2/28/27
End Date
Funding Split
$3.3M
Federal Obligation
$0.0
Non-Federal Obligation
$3.3M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R37CA258761
Transaction History
Modifications to R37CA258761
Additional Detail
Award ID FAIN
R37CA258761
SAI Number
R37CA258761-248915481
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Other
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
LMCJKRFW5R81
Awardee CAGE
3GQT6
Performance District
NY-26
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,398,035 | 100% |
Modified: 5/5/26